Orthopaedic & Rheumatologic Institute Outcomes
Surgical Quality Improvement
Total Hip Arthroplasty Outcomes
Total Hip Arthroplasty ACS NSQIP Outcomes
January 1, 2021 – December 31, 2021
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall total hip arthroplasty ACS NSQIP performance benchmarked against 468 participating sites.
| Total Hip Arthroplasty (468 sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Mortality | 290 | 0.69% | 0.37% |
| 30 Day Morbidity | 290 | 5.17% | 4.74% |
| Cardiac | 290 | 0.69% | 0.29% |
| Pneumonia | 290 | 1.38% | 0.50% |
| Unplanned Intubation | 290 | 0.69% | 0.21% |
| Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 290 | 2.07% | 0.97% |
| Renal Failureᵃ | 290 | 1.72% | 0.23% |
| Urinary Tract Infection (UTI) | 290 | 1.03% | 0.67% |
| Surgical Site Infection (SSI) | 290 | 0.69% | 2.09% |
| Sepsis | 290 | 0.69% | 0.39% |
| C.diff Colitis | 290 | 0.34% | 0.14% |
| Return to Operating Room (ROR) | 290 | 1.03% | 3.05% |
| Readmission | 290 | 6.55% | 5.58% |
American College of Surgeons National Surgical Quality Improvement Program, 2022.
ACS NSQIP® Semiannual Report July 12, 2022, Chicago: American College of Surgeons.
ᵃExemplary rating; Identified as a statistical outlier (higher than expected) by the ACS NSQIP hierarchical model
